In 2006, over 55,000 Americans are expected to die of colorectal cancer (CRC) (1). It is estimated that there is over a 5% chance that an American will develop CRC in their lifetime and over a 2% chance that an American will die from CRC (2). Fortunately, in most cases, controlling CRC is possible with the proper screening methods and the subsequent removal of suspicious polyps, adenomas, and carcinomas. If CRC is detected at an early stage, the 5-year survival rate is 90%. Unfortunately, less than 40% of colorectal cancers are detected at an early stage. Once the cancer has developed distant metastases, the 5-year survival rate is less than 10% (2).From 1998 to 2002, the incidence rate of CRC decreased by 1.8% per year, which is believed to have occurred due to increased awareness of the importance of CRC screening and consequent polyp removal (2). However, CRC is still predicted to cause about 10% of all cancer-related deaths in the United States in 2006. Relatively accurate screening methods are available to patients, but patient participation in CRC screening continues to be low. Computed tomography colonography (CTC) is a relatively new screening technology that aims to achieve a high patient acceptance, diagnostic accuracy, and screening effectiveness thereby decreasing mortality rates due to CRC.